Journal of Cancer Research and Therapeutic Oncology

Editorial Board (JCRTO)

Luca Gattinoni (NIH/NCI)
Luca Gattinoni (NIH/NCI)
Investigator
Center for Cancer Research
National Cancer Institute
United States
Tel. 301-451-6914
Biography
Dr. Gattinoni received his M.D. from the Universita' degli Studi of Milan, Italy. Following the completion of his residency in medical oncology at the Istituto Nazionale Tumori in Milan, he joined the NCI in 2003 as a Visiting Fellow and became a Staff Scientist in 2008. In 2013, Dr. Gattinoni was appointed as an Earl Stadtman Tenure-Track Investigator at the Experimental Transplantation and Immunology Branch. His research interest is in T-cell-based immunotherapies with an emphasis on T-cell differentiation and transcriptional regulation of T-cell self-renewal and memory formation.
Publications
Investigator
Center for Cancer Research
National Cancer Institute
United States
Tel. 301-451-6914
Research Interest
T-cell-based immunotherapies with an emphasis on T-cell differentiation and transcriptional regulation of T-cell self-renewal and memory formation
James M. Phang (NIH/NCI)
James M. Phang (NIH/NCI)
Head, Metabolism & Cancer Susceptibility Section
Center for Cancer Research
United States
Tel: (301)-846-5367
Biography
Dr. James Phang received his M.D. from Loma Linda University School of Medicine and his clinical training in internal medicine from Stanford Medical Center. He was a clinical associate with the NCI's Metabolism Branch. After additional training in biochemistry and molecular biology with the Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Dr. Phang was appointed a senior investigator in the Metabolism Branch, NCI, and later became chief of the Endocrinology Section. From 1989 to 1998, he served as chief of the Laboratory of Nutritional and Molecular Regulation, and in 1998, he formed the Metabolism and Cancer Susceptibility Section in the Basic Research Laboratory. The Section joined the Laboratory of Comparative Carcinogenesis in 2003.
Publications
Head, Metabolism & Cancer Susceptibility Section
Center for Cancer Research
United States
Tel: (301)-846-5367
Research Interest
Metabolic Mechanisms for Modulating the Cancer Susceptible Phenotype, The Apc Genotype in Colorectal Carcinogenesis and Modulation of the Phenotype by Nitric Oxide, Proline and Pyrroline-5-Carboxylate in Cell Regulation, Prolidase renders proline (hydroxyproline) from extracellular matrix degradation
Dimiter S. Dimitrov (NIH/NCI)
Dimiter S. Dimitrov (NIH/NCI)
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States
Tel: (301)-846-1352
Biography
Dr. Dimitrov joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990, was tenured as Senior Investigator in 1993 and appointed at the Senior Biomedical Research Service in 2008. His research group includes molecular biologists who are experts in display/screening/libraries methodologies, antibody engineering, and protein biochemistry, structural biologist and computational scientist. His major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies including engineered antibody domains. He has authored and coauthored more than 300 articles cited about 10,000 times, and is inventor or coinventor of more than 50 inventions, patent applications or patents. See also his web site http://ccr.cancer.gov/staff/staff.asp?profileid=5749
Publications
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States
Tel: (301)-846-1352
Research Interest
Development of human monoclonal antibodies including isolated engineered antibody domains for prevention and treatment of cancer and other diseases
Wafik El-Deiry
Wafik El-Deiry
Professor
Penn State Hershey Cancer Institute
United States
Tel: (610)-800-2443
Biography
Dr. Wafik El-Deiry, MD, PhD, FACP is the Rose Dunlap Professor of Medicine and Chief of the Hematology/Oncology Division at the Penn State University Milton S. Hershey Medical Center and Penn State College of Medicine, Associate Director for Translational Research and Program Leader of Experimental Therapeutics at the Penn State Hershey Cancer Institute. Dr. El-Deiry is also one of 40 active American Cancer Society Research Professors. Dr. El-Deiry earned his MD and PhD degrees from the University of Miami and completed internal medicine residency at the Johns Hopkins Hospital and then completed oncology fellowship training at the Johns Hopkins Oncology Center in Baltimore. He discovered p21(WAF1) as a p53 target gene, universal cell cycle inhibitor and tumor suppressor gene that for the first time explained the mammalian cell stress response. This is the most highly cited original work published in the prestigious journal Cell over the last 20 years. Dr. El-Deiry joined the faculty at the University Of Pennsylvania School Of Medicine as Assistant Professor of Medicine and Genetics in 1994, Associate Professor with tenure in 1999 and rose to full Professor of Medicine, Pharmacology and Genetics with tenure by 2005. He was an Investigator with the Howard Hughes Medical Institute from 1995-2004. He served as co-Program Leader of the Radiobiology & Imaging Program at the Abramson Cancer Center and as Associate Director for Physician-Scientist Training in Hematology/Oncology at the University of Pennsylvania. He made several discoveries in the field of cell death and tumor suppressor genes including discovery of TRAIL death receptor DR5 as a target of the p53 tumor suppressor. Dr. El-Deiry’s laboratory has also developed a functional small molecule discovery screening and in vivo validation/efficacy testing process for accelerating the identification and development of molecularly-targeted anti-cancer therapeutic agents. He has over 300 peer reviewed publications. He has been very active in serving on journal editorial boards including as Associate Editor for the Journal of Clinical Investigation from 2007-2010 and as the Editor-in-Chief of Cancer Biology and Therapy from 2001 to the present. Dr. El-Deiry is very active in the NIH review system, lectures widely throughout the world and was named as a highly cited researcher by Thompson ISI in the field of molecular biology and genetics in 2005 and as one of America's Top Oncologists by the Consumer Research Council of America in 2008 and 2009. He is a member of the Faculty of 1000 in Cell Growth and Division. He is a member of several national physician honor societies including the Interurban Clinical Club, the American Society of Clinical Investigation and the American Association of Physicians. He has organized several international meetings and has won several awards including the 2010 international Kuwait Prize in Applied Sciences for "Cancer Diseases." He is a practicing physician-scientist who specializes in colorectal cancer treatment.
Publications
Professor
Penn State Hershey Cancer Institute
United States
Tel: (610)-800-2443
Research Interest
Drug resistance in cancer, cell death, tumor suppressor genes, cell cycle, translational research, cancer stem cells, tumor microenvironment, hypoxia, p53, TRAIL, c-Myc, BRCA1, molecular imaging, drug discovery
Shufeng Zhou
Shufeng Zhou
Professor
University of South Florida
United States
Biography
Professor Zhou is presently the Associate Vice President of Global Medical Development & Associate Dean of International Research, College of Pharmacy, University of South Florida, Tampa (USF), Florida.Professor Zhou completed his clinical medical training in China in 1989 and obtained his PhD in 2001 from the School of Medicine, the University of Auckland, New Zealand. Since 2002, Dr Zhou has served as an Assistant Professor, Senior Lecturer, Associate Professor and Professor for the National University of Singapore, Queensland University of Technology, and RMIT University in Australia. Professor Zhou has published more than 350 peer-reviewed papers in various pharmacology and medical journals including New England Journal of Medicine, Cancer Research, Journal of Biological Chemistry, Clinical Pharmacology and Therapeutics, and Clinical Cancer Research. He has also published 18 books and book chapters and more than 320 conference abstracts. His work has been cited more than 9,400 times by other colleagues with an H-index of 47. Dr Zhou has given more than 120 invited seminars/keynote presentations to a variety of academic institutes, government agencies, and high-profile international conferences. He has received more than US$25.0 million grants from various funding bodies and industries.He is a recipient of several national and international awards, a council member of US Pharmacopoeia and advisor of World Health Organization (WHO), a council member or chair of several national and international professional societies, and a visiting/adjunct professor of multiple reputable research universities around the world.
Publications
Professor
University of South Florida
United States
Research Interest
Systems pharmacology, drug metabolism & drug transport, pharmacokinetics/pharmacometrics, pharmacogenomics, nanomedicine and Chinese medicine.
Guido Kroemer
Guido Kroemer
Research Director
French Medical Research Council
Institut Gustave Roussy
France
Tel: +33-1- 42 11 60 46
Biography
Guido Kroemer is currently a Research Director at the French Medical Research Council (INSERM), and the Director of the Research Unit "Apoptosis, Cancer and Immunity" at the Institut Gustave Roussy located in Villejuif, near to Paris, France. Prior to joining the INSERM (1993), Dr. Kroemer was Senior Scientist of the European Community at the Spanish National Research Council (CSIC), at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). Dr. Kroemer did his post-doctoral training in the College de France, Nogent-sur-Marne (1988-1989) and at the University of Innsbruck, Austria, after receiving his Ph.D/M.D. degree at the same University in 1985. He also holds a Ph.D. degree in Biology (Autonomous University of Madrid, 1992). Guido Kroemer's team discovered in 1994 that mitochondrial membrane permeabilization is a critical step in programmed cell death. His current research focuses on pathogenic derangements of programmed cell death, the pathophysiology of autophagy, the molecular perturbations of cancer cell apoptosis, the pharmacological induction of apoptosis and the role of immunogenic cell death in anticancer therapy. Guido Kroemer is currently the most cited scientist worldwide in the field of cell death . He is member of EMBO, German Academy of Sciences (Leopoldina), Academia Europaea, European Academy of Sciences (EAS), and European Academy of Sciences and Arts (EASA). He is the President elect of the European Cell Death Organization (ECDO) and the Founding Director of the European Research Institute for Integrated Cellular Pathology (ERI-ICP). Kroemer received the 2006 Descartes Prize, the highest scientific distinction of the European Union, for his fundamental discoveries in the field of programmed cell death (apoptosis). He also received one of the Grands Prix from the French Academy of Sciences in 2007, the Carus Medal 2008 from the German Academy of Sciences, and the Dautrebande Prize 2009 from the Belgian Royal Academy of Medicine.
Publications
Research Director
French Medical Research Council
Institut Gustave Roussy
France
Tel: +33-1- 42 11 60 46
Research Interest
Apoptosis, cancer research, cell biology, molecular biology, immunology
Jing Huang (NIH/NCI)
Jing Huang (NIH/NCI)
Principal Investigator
Cancer and Stem Cell Epigenetics
National Cancer Institute
United States
Tel: (301)-496-2202
Biography
Dr. Huang received his BS in Biochemistry from Peking University. He studied estrogen receptor signaling with Drs. Robert Bambara and Mesut Muyan at the University of Rochester (NY) and received his PhD in 2004. After his postdoctoral training in cancer epigenetics with Dr. Shelley Berger at the Wistar Institute, he joined the Laboratory of Cancer Biology and Genetics as a tenure-track Principal Investigator in October, 2008. Dr. Huang won a NCI Director's Innovation Award with Dr. Jianxin Shi (DCEG) in 2011.
Publications
Principal Investigator
Cancer and Stem Cell Epigenetics
National Cancer Institute
United States
Tel: (301)-496-2202
Research Interest
Stem cell differentiation, cancer stem cells, and differentiation
Carlos Martinez-A
Carlos Martinez-A
Professor
Spanish National Research Council
National Center for Biotechnology
Madrid/Spain
Tel: (+34 91) 585-4559/4850/4537
Biography
Carlos Martinez-A. is professor of Immunology at the CSIC, Spain and former President of the Spanish National Research Council (CSIC) and Secretary of State for Research and Innovation. He earned his Ph.D. in 1978 from the Clinica Puerta de Hierro and the Universidad Complutense in Madrid, Spain. He was a member of the Basel Institute for Immunology until 1981, and subsequently held research positions at the University of Umea, Sweden, the Clinica Puerta de Hierro, Spain, and the Centre National de la Recherche Scientifique, Paris, France. He has been visiting professor at the Ontario Cancer Institute, Toronto, Canada, the Max Planck Institute for Immunology in Freiburg, Germany, and the California Institute of Technology, USA. He became Full Professor at the Spanish Council for Scientific Research (CSIC) in 1986, working first in the Centro de Biologia Molecular and later in the Centro Nacional de Biotecnologia, where he formed the Department of Immunology and Oncology (DIO) in 1993. Dr. Martinez has studied leukocytes in several fields from cellular immunology to autoimmune disease. With his co-workers, he has studied lymphocyte activation, the role of chemotactic responses in physiological and pathological settings, and the molecular mechanisms implicated in the control of cell death and autoimmunity. He is member of EMBO, former member of the EMBO Scientific Council, President of European Molecular Biology Conference and member of the Academia Europaea and holds many prestigious awards.
Publications
Professor
Spanish National Research Council
National Center for Biotechnology
Madrid/Spain
Tel: (+34 91) 585-4559/4850/4537
Research Interest
Stem cell biology, focusing mostly on genomic instability, and their implications in cancer and immunoregulation.
Bijan Najafi
Bijan Najafi
Associate Professor
University of Arizona
United States
Tel: (520) 626-7097
Biography
Dr Bijan Najafi is currently serving as Associate Professor of Surgery and Engineering as well as the Director of interdisciplinary Consortium on Advanced Motion Performance (iCAMP). He has over a decade experience in designing bio-inspired sensors for objective evaluation of healthy state of patients with locomotor dysfunction, over 60 scientific publications in peer reviewed journals with more than 1700 citations, 7 patents or pending patents, and PI or key investigator on over 10 active grants including industrial, national and international grants. His unique expertise is the translation of wearable sensors for more accurate movement assessment of patients in their natural environment where they're the most comfortable and active. His goal, which he shares with his iCAMP colleagues, is to better understand how people move through their environment. In this way, he believes, he may be able to fundamentally change the way we objectively measure quality of life for people across disciplines.
Publications
Associate Professor
University of Arizona
United States
Tel: (520) 626-7097
Research Interest
Biomechanics and biomechanical modeling, Balance, Gait, and Outcome research, Biosignal processing, Bioinformatics and Personal health networks, Fall prevention, Elderly care, Frailty assessment and Motor performance
Seigo Kinuya
Seigo Kinuya
Professor
Department of Nuclear Medicine
Kanazawa University
Japan
Tel: +81 76-265-2333
Biography
Publications
Professor
Department of Nuclear Medicine
Kanazawa University
Japan
Tel: +81 76-265-2333
Research Interest
Nuclear Medicine, Positron emission tomography, Single photon emission computed tomography, Targeted radiotherapy, Radionuclide therapy, Radioimmunotargeting, Radioimmunotherapy
Wassana Yantasee
Wassana Yantasee
Associate Professor
OHSU School of Medicine
United States
Tel: (503) 418-9306
Biography
Yantasee graduated from Oregon State University with MS (1999) and PhD (2001) in Chemical Engineering as well as MBA (2001). She had worked as a Research Scientist at the Pacific Northwest National Laboratory (PNNL) for 8 years. Currently she is an Associate Professor of Biomedical Engineering at Oregon Health and Science University (OHSU) School of Medicine. Her research interest is in the development of nanomaterials for cancer therapeutics and diagnosis. She is also the President of PDX Pharmaceuticals, a biotech company specialized in siRNA-nanoparticle based cancer therapies. She has been a scientific reviewer for NIH’s Biomaterials and Biointerfaces (charter member) and many other panels for NIH and DOE.
Publications
Associate Professor
OHSU School of Medicine
United States
Tel: (503) 418-9306
Research Interest
1. Functional nanomaterials for biomedical applications and medicine
2. Target delivery of drugs and siRNA using nanoparticles for cancer therapies
3. Metals in medicine (iron overload, nephrogenic systemic fibrosis linked to gadolinium based contrast agents, hyperphosphatemia, and heavy metal poisoning).
4. Development of portable metal analyzers for biomonitoring of toxic metal exposure
David A. Boothman
David A. Boothman
Professor
Pharmacology and Radiation Oncology
University of Texas Southwestern
United States
Tel: (214)-645-6371
Biography
Dr. Boothman received his Ph.D. in Microbiology and Immunology (Mentor: Dr. Sheldon Greer), University of Miami Medical School, focusing on the Biochemistry and Pharmacology of anticancer drugs, specifically 5-fluorouracil derivatives. He then traveled to the Dana-Farber Cancer Institute, Harvard Medical School to train with Dr. Arthur B. Pardee. He investigated the cell cycle checkpoint regulation, molecular biology and gene expression changes in cancer cells before and after cell stress. Studies on ß-lapachone as a radiosensitizer and DNA repair inhibitor were initiated at this time. Dr. Boothman also discovered and cloned the first ionizing radiation (IR)-inducible proteins and transcripts. Dr. Boothman accepted his first Assistant Professor position at the University of Michigan-Ann Arbor and continued his investigations of x-ray-inducible proteins, discovering xip8, clusterin, and its induction by super-low levels of IR exposure. Dr. Boothman then joined the faculty in the Department of Human Oncology at the University of Wisconsin-Madison, where he rose to Associate Professor with tenure and became the Vice Chairman of Radiation Oncology, Division Head of Molecular Radiation Oncology. In 1998, Dr. Boothman accepted an Endowed Professorship at Case Western Reserve University and became heavily involved in the Cancer Center. Dr. Boothman’s laboratory is supported by grants from the Department of Defense, Department of Energy and the National Institutes of Health.
Publications
Professor
Pharmacology and Radiation Oncology
University of Texas Southwestern
United States
Tel: (214)-645-6371
Research Interest
Cellular and molecular biology of DNA repair and damage-inducible responses in mammalian cells, cellular and molecular biology of eukaryotic gene expression and the role(s) of X-ray-inducible genes in cell cycle regulation and apoptosis, Development of novel delivery methodology, including nanoparticle micelles, cRGD-containing nanoparticles, and millirods, Role of DNA mismatch repair, specifically MLH1, in G2/M cell cycle control and apoptosis, changes in gene expression during aging and the involvement of failing DNA repair processes in aging, cellular and molecular biology of cell cycle checkpoint responses.
Stefan Wiemann
Stefan Wiemann
Professor and Head
Division Molecular Genome Analysis
German Cancer Research Center
Germany
Biography
Stefan Wiemann earned his PhD from the University of Kaiserslautern and the German Cancer Research Center Heidelberg on the cloning of isoforms of cAMP-dependent protein kinase. He was visiting scientist at the European Molecular Biology Laboratory from 1992-1995, where he contributed to the genome sequencing of the first eukaryote (S.cerevisiae) as well as to the development of sequencing technologies. He then joined the DKFZ to set up a pipeline for the systematic analysis of human genes. Since 2008 he has been head of the division Molecular Genome Analysis and as of 2010 also of the Genomics and Proteomics Core Facility of the DKFZ. He has led large research networks in national DHGP and NGFN funding programs and is partner in international consortia. He coordinated the German cDNA Consortium, the largest initiative for cDNA generation and sequencing in Europe. Building on these cDNA resources, functional genomic projects were established aimed to analyze the localization and activities of encoded proteins. In the recent years, his focus has shifted to the investigation of molecular events during breast cancer development and progression, and on the mechanistic impact proteins and miRNAs have in these processes. Major emphasis of his lab is on the regulation of cellular signaling pathways and networks in tumor development, drug resistance, and metastasis. The Genomics and Proteomics Core Facility operates one of the largest next generation sequencing units in Europe, having a focus on genome, exome and RNA sequencing of clinical specimen. Along these lines, Stefan Wiemann is partner in an interdisciplinary consortium that aims to develop guidelines for dealing with the ethical and legal implications NGS imposes on genetic testing of individuals.
Publications
Professor and Head
Division Molecular Genome Analysis
German Cancer Research Center
Germany
Research Interest
Breast cancer, signaling networks, mechanisms of drug resistance and metastasis, tumor-microenvironment interactions, miRNAs, genomics and proteomics technologies, ethics of genome-wide genetic testing
Justin Sturge
Justin Sturge
Senior Lecturer
Translational Oncology
University of Hull
United Kingdom
Tel: 01482 465316
Biography
Dr Justin Sturge is a Principal Investigator and Senior Lecturer in Biomedical Science & Translational Oncology who heads the Tumor Stroma & Metastasis Laboratory located in The Allam Building within The School of Biological, Biomedical & Environmental Sciences at The University of Hull (UK) where he has been based since March 2012. Dr Sturge has been Honorary Non-Clinical Lecturer at Imperial College London (UK) since October 2011. Dr Sturge was Principal Investigator and Non-Clinical Lecturer, heading the Metastasis Team in the Division of Cancer, Department of Surgery & Cancer and Imperial College London (April 2006 – October 2011). He completed his PhD studies at the National Heart & Lung Institute, Imperial College London (UK) in 1998. His post-doctoral research was conducted at the Breakthrough Breast Cancer Research Center at the Institute of Cancer Research, London (UK) (2001-2006) and The Randall Center for Molecular Mechanisms of Cell Function, King's College London (UK) (1998-2001).
Publications
Senior Lecturer
Translational Oncology
University of Hull
United Kingdom
Tel: 01482 465316
Research Interest
Dr Sturge’s research is focused on understanding the molecular mechanisms of prostate and breast cancer progression and translating these findings to the clinical setting. The specific focus of his work is to define the bidirectional communication pathways that establish between tumour cells and the stromal compartment of the primary tumour (fibroblasts, immune cells, extracellular matrix) and secondary tumours in the bone (osteoblasts, osteoclasts, mineralised extracellular matrix).
Takeo Nakanishi
Takeo Nakanishi
Associate Professor
School of Pharmaceutical Sciences
Kanazawa University
Japan
Tel: +81-76-234-4478
Biography
Publications
Associate Professor
School of Pharmaceutical Sciences
Kanazawa University
Japan
Tel: +81-76-234-4478
Research Interest
Regulation of BCRP/ABCG2 gene expression in human tissues and cancer, Role of LAT1 (SLC7A5) in cell survival of malignant tumors
Motomi Mori
Motomi Mori
Professor
Oregon Health & Science University
United States
Tel: (503)418-1555
Biography
Motomi Mori, PhD, is a Professor and Head of the Division of Biostatistics, Department of Public Health & Preventive Medicine (PHPM), Walter & Clora Brownfield Endowed Professor of Cancer Biostatistics, and the Director of the Biostatistics Shared Resource of the Knight Cancer Institute at OHSU. After receiving her PhD in Biostatistics from the University of Iowa in 1989, Dr. Mori joined the Fred Hutchinson Cancer Research Center as an Assistant Member and as a Research Assistant Professor in the Department of Biostatistics at the University of Washington. She was recruited as a lead biostatistician for the Huntsman Cancer Institute (HCI) at the University of Utah in 1991. During her time at the HCI, she developed a research collaboration with the Blood and Marrow Transplant Program at the University of Utah and the National Marrow Donors Program (NMDP) to estimate an optimum racial composition and size of the marrow donor registry for enhanced access to human leukocyte antigen (HLA)-matched donors among minority patients in the United States (R01HL56368 Implications of HLA Polymorphism for Donor Recruitment). Dr. Mori was recruited to direct the Biostatistics Shared Resource of the Oregon Cancer Center (now the Knight Cancer Institute) in 1999. Nationally she served as a member of the NCI Subcommittee A (Cancer Centers of the National Cancer Institute Initial Review Group). She is a Fellow of the American Statistical Association and serves on the Editorial Boards for the Clinical & Translational Science and Open Access Bioinformatics. She is a successful biostatistician collaborator with over 110 publications and 24 years of experience in cancer research.
Publications
Professor
Oregon Health & Science University
United States
Tel: (503)418-1555
Research Interest
Current research interest includes clinical trial designs for molecularly targeted agents, biomarker validation and evaluation of personalized medicine in treatment and prevention settings.
Xiangshu Xiao
Xiangshu Xiao
Physiology & Pharmacology
Oregon Health & Science University
United States
Tel: 503-494-4748
Biography
Publications
Physiology & Pharmacology
Oregon Health & Science University
United States
Tel: 503-494-4748
Research Interest
Chemical biology, medicinal chemistry, discovery of novel anticancer agents.
Peter Lobie
Peter Lobie
Professor
Cancer Science Institute of Singapore
National University of Singapore
Singapore
Tel: +65-66011046
Biography
Peter Lobie obtained a B.Med.Sci. (Distinction) and MBBS (Medicine First Class Honours) in 1992 from the University of Queensland in Australia. He was awarded the highest accolade from the University in the form of a University Medal. His postdoctoral work was undertaken at the Karolinska Institute in Sweden where he also obtained a PhD. He has consecutively held faculty positions in Singapore and New Zealand. He was also New Zealand’s first chair of Breast Cancer funded by the Breast Cancer Research Trust. He is now is Professor and Senior Principal Investigator at the newly formed Cancer Science Institute of Singapore. Peter Lobie is author of over 120 publications and is an international authority on molecular mechanisms of hormone action. He is the recipient of multiple local and international awards and has been appointed a Fellow (Academician) of the Royal Society of New Zealand. Prof. Lobie is the inventor on 11 patent families and has been associated heavily with industry during his time in Sweden (Pharmacia), has consulted for Pfizer Inc. and Metabolic Inc. and in New Zealand served as a senior consultant to Neuren Pharmaceuticals as head of their cancer research programme. He is the founding scientist of Perseis Therapeutics Ltd and Saratan Therapeutics Ltd, two new entities focused on development of therapeutics to novel cancer target molecules. He is also a founding shareholder in Wuhan Long Ke Ltd. He was an editorial board member of Endocrinology among a number of other international journals and served on the Annual Meeting Steering Committee of The Endocrine Society (USA). He has served as a reviewer for more than 40 academic journals and more than 15 local and international granting agencies.
Publications
Professor
Cancer Science Institute of Singapore
National University of Singapore
Singapore
Tel: +65-66011046
Research Interest
Peter Lobie’s research focuses on the capacity of hormones or secreted proteins to initiate or progress cancer, particularly breast and endometrial carcinoma.
Stephen G. Maher
Stephen G. Maher
Senior Lecturer
Biomedical Science
University of Hull
United Kingdom
Tel: +44 (0) 1482 46 6543
Biography
Dr Stephen Maher received a PhD in Oncology from the Royal College of Surgeons in Ireland in 2004, focusing on T-cell biology and IL-2 immunotherapy of cancer. He subsequently undertook post-doctoral training in the USA as a visiting fellow at the NCI Center for Cancer Research, where he studied STAT signaling and interferon therapy of cancer. In 2007 joined Trinity College Dublin, as a senior research fellow, and later as an Irish Cancer Society Research Fellow. Dr Maher is currently a Senior Lecturer in Biomedical Science at the University of Hull and an adjunct Associate Professor with the Department of Surgery at Trinity College Dublin. The continued translational research focus of his Irish and UK-based groups is oesophageal cancer, with a particular emphasis on understanding the molecular and cellular biology (including microRNA dysregulation, mitochondrial dysfunction, cancer stem cell biology) behind resistance to chemoradiotherapy in patients, the immune microenvironment of Barrett’s oesophagus and tumour progression. He has won numerous national and international awards for his work in this area.
Publications
Senior Lecturer
Biomedical Science
University of Hull
United Kingdom
Tel: +44 (0) 1482 46 6543
Research Interest
Patient-orientated cancer biology, tumour immunology and cancer therapeutics
Lucia Altucci
Lucia Altucci
Professor
Department of Pathology
Second University of Naples
Italy
Tel: +39 081-5667569
Biography
Publications
Professor
Department of Pathology
Second University of Naples
Italy
Tel: +39 081-5667569
Research Interest
Translational Medicine, Mechanism of growth regulation, differentiation and apoptosis by epigenetic drugs and nuclear receptors signaling.
Taro Yamashita
Taro Yamashita
Assistant Professor
Department of General Medicine
Kanazawa University Hospital
Japan
Tel: 076-265-2042
Biography
Publications
Assistant Professor
Department of General Medicine
Kanazawa University Hospital
Japan
Tel: 076-265-2042
Research Interest
Gastrointestinal/Hepatobiliary Malignancy, Cancer Stem Cell, Gene Expression Profiling, Translational Oncology
Isabel M Pires
Isabel M Pires
Lecturer
Biomedical Science
University of Hull
United Kingdom
Tel: +44 (0)1482 466656
Biography
Dr. Isabel Pires received her PhD in Pharmacology from the University of Manchester, where she first developed her interest in translational research and targeted therapies in Prof. Caroline Dive’s lab. In 2007 she moved to Dr. Ester Hammond’s lab in the Gray Institute for Radiation Oncology and Biology, Oxford University, where her work focused on investigating and therapeutically exploiting the biology of hypoxic tumors. There she developed her current interest in the role of hypoxia in metastatic cancer progression. Dr. Pires is currently the Principal Investigator of the Hypoxia and Tumor Microenvironment group and a Lecturer in Biomedical Science at the University of Hull.
Publications
Lecturer
Biomedical Science
University of Hull
United Kingdom
Tel: +44 (0)1482 466656
Research Interest
Hypoxia and the tumor microenvironment, metastasis, targeted therapies
David J. Riese II
David J. Riese II
Gilliland and Franklin Professor
Harrison School of Pharmacy
Auburn University
Tel: (334)-844-8358
Biography
Dr. David Riese received a PhD in Genetics from Yale University, where he investigated the oncogenic activities of papillomavirus genes under the tutelage of Dr. Daniel DiMaio and demonstrated that the PDGF receptor signaling pathway is required for transformation of fibroblasts by the Bovine Papillomavirus E5 protein. He subsequently pursued postdoctoral training in Pathology at Yale University, where he studied interactions of EGF family peptide growth factors with ErbB family receptor tyrosine kinases under the tutelage of Dr. David F. Stern. He then joined the faculty at Purdue University, where he was affiliated with the College of Pharmacy and the NCI-designated Center for Cancer Research. Since 2010 he has been the Gilliland and Franklin Professor of Pharmacal Sciences at the Auburn University Harrison School of Pharmacy, where he also holds the position of Associate Dean for Research and Graduate Programs. Dr. Riese's laboratory continues to study signaling by EGF family hormones and ErbB family receptors, with a focus on the EGFR/ErbB1 and ErbB4/HER4 receptor tyrosine kinases and their growth factor ligands.
Publications
Gilliland and Franklin Professor
Harrison School of Pharmacy
Auburn University
Tel: (334)-844-8358
Research Interest
ERBB4 and Epithelial Tumors, EGF Family Hormones, EGFR Mutants and Human Malignancies
Harukuni Tokuda
Harukuni Tokuda
Associate Professor
Department of Complementary and Alternative Medicine Clinical R & D
Kanazawa University
Japan
Biography
Publications
Associate Professor
Department of Complementary and Alternative Medicine Clinical R & D
Kanazawa University
Japan
Research Interest
Chemopreventive studies using natural source materials
Julian J. Lum
Julian J. Lum
Scientist
BC Cancer Agency
University of Victoria
Canada
Tel: (250)-519-5718
Biography
Dr. Lum has PhD from the University of Ottawa in Microbiology and Immunology where he studied the regulation of death receptor-mediated apoptosis of CD4 T cells. His work focused on TNF-Related Apoptosis Inducing Ligand (TRAIL) during HIV infection. In 2003, Dr. Lum pursued post-doctoral training with Craig B. Thompson at the University of Pennsylvania where they studied how metabolic stress regulates autophagy and consequentially T cell function. Dr. Lum was recruited to the BC Cancer Agency in 2008 where he is studying the interplay between the tumor microenvironment and the immune system. He is studying how autophagy is regulated and whether metabolic conditions can skew T cell differentiation, function and memory T cell generation. Finally, his laboratory is interested in understanding how radiation therapy impacts the anti-tumor response in prostate and ovarian cancer. Dr. Lum is a CIHR New Investigator and holds grants from CIHR, CRS, DoD, Genome BC, and local cancer charities and organizations. Keywords: Autophagy, T cell immunotherapy, radiation treatment, T cell metabolism, angiogenesis, hypoxia, tumor metabolism.
Publications
Scientist
BC Cancer Agency
University of Victoria
Canada
Tel: (250)-519-5718
Research Interest
Cancer Metabolism, Tumor Immunology, Autophagy, Memory T cells
Mario Otto
Mario Otto
Assistant Professor
Pediatric Hematology/Oncology
University of Wisconsin-Madison
United States
Tel: (608)-265-9645
Biography
Publications
Assistant Professor
Pediatric Hematology/Oncology
University of Wisconsin-Madison
United States
Tel: (608)-265-9645
Research Interest
Pediatric Oncology, Immunotherapy and targeted therapies for (pediatric) cancer, Stem Cell Transplantation, Nano-Oncology/Nanotechnology for Oncology
Satoru Kyo
Satoru Kyo
Clinical Professor
Department of Obstetrics and Gynecology
Kanazawa University
Japan
Biography
Publications
Clinical Professor
Department of Obstetrics and Gynecology
Kanazawa University
Japan
Research Interest
Telomeres and telomerase in cancer, Molecular carcinogenesis and pathogenesis, Gynecologic oncology
Yuzhuo Wang
Yuzhuo Wang
Senior Scientist
BC Cancer Agency
University of British Columbia
Canada
Tel: (604-)675-8013
Biography
Dr. Yuzhuo Wang has a dual appointment as a Senior Scientist at Vancouver Prostate Centre and BC Cancer Agency. He is also the Founder of the Living Tumor Laboratory (www.livingtumorlab.com) and an Associate Professor in Department of Urological Sciences at UBC. Dr. Wang did his Ph.D. at the University of Hong Kong, and joined Dr. Gerald R Cunha at University of California, San Francisco as a postdoctoral fellow in 1997. Since then, he has authored/co-authored over 90 peer-reviewed original articles and review papers, including publications in Cancer Research, PNAS, Cancer Cell, Clinical Cancer Research, the EMBO Journal, Oncogene, and the FASEB journal. As a principal investigator, he is well funded by a number of agencies (e.g., the Canadian Institutes of Health Research). In addition to proposing novel hypotheses on “prostate stem cells” and “epithelial-immune cell transition (EIT)”, Dr. Wang is recognized for his pioneering work in the field of prostate cancer modeling, he was the first to establish tissue recombination model of hormonal prostatic carcinogenesis. He also developed the first model of hormonal carcinogenesis in human prostatic epithelium. Moreover, he is responsible for a novel method for establishing transplantable, patient-derived xenograft models that closely resemble patients’ malignancies. Using the methodology, his group has developed over 180 transplantable patient-derived xenograft models in the laboratory. Importantly such “next generation” xenograft models have been effectively applied in a number of research areas, such as (i) preclinical drug efficacy studies in anti-cancer therapeutics development, (ii) discovery and validation of potential biomarkers and/or therapeutic targets, and (iii) personalized cancer therapy. Dr. Wang has received numerous awards for his academic achievements in cancer research, such as a Prostate Cancer Foundation Research Award, US (2007), the Translation Research Award from Roche Canada (2009), an Overseas Chinese Scholars Award (Distinguished Young Scholar Award, Category B) from the National Natural Science Foundation of China (2009), the Innovative Scholar Award from the International Cancer Alliance for Research and Education (ICARE), US (2010), an UBC Faculty of Medicine Distinguished Achievement Award, Canada (2011).
Publications
Senior Scientist
BC Cancer Agency
University of British Columbia
Canada
Tel: (604-)675-8013
Research Interest
Translational oncology; Personalized cancer therapy; Development of novel therapeutic; Cancer discovery; Patient derived xenograft models; Prostate cancer
Thomas G. Hofmann
Thomas G. Hofmann
Head
Cellular Senescence Group
German Cancer Research Center
DKFZ-ZMBH Alliance
Germany
Biography
Publications
Head
Cellular Senescence Group
German Cancer Research Center
DKFZ-ZMBH Alliance
Germany
Research Interest
DNA damage signaling; Mechanisms of radio- and chemosensitivity; apoptosis; cellular senescence; checkpoint kinases, p53.
Bing Zhu
Bing Zhu
Assistant Professor
Mitchell Cancer Institute
Drug Discovery Research Center
United States
Tel: 251-445-8416
Biography
Dr. Zhu has worked in the areas of carcinogenesis and cancer chemoprevention since 1996. His major research expertise is in the field of cyclic nucleotide signaling and phosphodiesterase isozymes that control tumor cell proliferation and apoptosis. Dr. Zhu received a Ph.D. in pharmacology from Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China in 1996. Dr. Zhu held a position as Assistant Professor for anti-tumor drug studies in Beijing Medical University, Chinese National Key Laboratory from 1996-1997. Dr. Zhu joined the University of South Alabama as a postdoctoral fellow from 1997-2002 and served as an independent investigator from 2002-2005. Dr. Zhu became a faculty member and a principal investigator in the Department of Pharmacology and Center for Lung Biology of University of South Alabama in 2005. Dr. Zhu held an Assistant Professor position from 2008-2011 and led several research projects in studies of the pharmacology and cell biology of tumor and endothelial cell models, which were supported by intramural and extramural funding from NIH and AHA resources. In November 2011, Dr. Zhu joined the Drug Discovery Research Center at the Mitchell Cancer Institute. Dr. Zhu’s studies are focused on understanding the basis of cell signaling transduction and compartmentalization for the cancer biology, chemotherapy and chemoprevention and the development of novel drugs with the potential for improved safety and efficacy in clinical application. Dr. Zhu has a special experience in tumorigenesis, chemoprevention, cancer biology, cyclic nucleotides and phosphodiesterase, especially in lung cancer area and related normal lung biology.
Publications
Assistant Professor
Mitchell Cancer Institute
Drug Discovery Research Center
United States
Tel: 251-445-8416
Research Interest
Cancer chemoprevention and anti-cancer drug development; Phosphodiesterases and cAMP/cGMP signaling in cancer biology; Intracellular signaling compartmentalization and anti-cancer therapy; Angiogenesis of cancer cells and normal tissues.
Mariusz Karbowski
Mariusz Karbowski
Assistant Professor
University of Maryland School of Medicine
United States
Tel: (410)-706-4018
Biography
Mariusz Karbowski received his Ph.D. in Molecular Pathology at Nagoya University School of Medicine, Nagoya, Japan, where his research focused on reactive oxygen species-related pathophysiology in mitochondria. He then went on to a postdoctoral fellowship at the National Institute of Neurological Disorders and Stroke, National Institutes of Health. During that time his research centered on the regulation of the mitochondrial steps in apoptosis and the cross talk between apoptosis induction and mechanisms regulating mitochondrial membrane fusion and fission. Dr. Karbowski is now on the faculty of the University of Maryland where his research group focuses on understanding the mechanisms of mitochondrial quality control and the regulation of mitochondrial membrane dynamics. Most of his research centers around the role of the ubiquitin conjugation system in mitochondrial steps in apoptosis, mitochondrial membrane dynamics and other mitochondrial pathways. Throughout his career, Dr. Karbowski has developed novel imaging methods and tools, and has applied them to questions that have advanced mitochondrial biology in innovative and important new directions.
Publications
Assistant Professor
University of Maryland School of Medicine
United States
Tel: (410)-706-4018
Research Interest
Stem Cell Biology, Regenerative Medicine, Molecular Pathology, Mitochondrial Function, Protein Cycling
Lorenzo Galluzzi
Lorenzo Galluzzi
Manager
LabEx ImmunoOncologie
Université Paris Descartes/Paris V
France
Tel: +33-1-4211-4516
Biography
Lorenzo Galluzzi (1980) obtained his Ph.D. in Molecular Oncology from the University of Paris Sud/Paris XI in 2008 and is currently the Research Manager of the LabEx ImmunoOncologie, a multi-laboratory French institution based in Paris, France. Alongside, Dr. Galluzzi works as part of the Research Unit "Apoptosis, Cancer and Immunity", directed by Dr. Guido Kroemer, and as an Editor-in-Chief/Specialty Chief Editor for OncoImmunology (LandesBioscience) and Frontiers in Molecular and Cellular Oncology (Frontiers). Dr. Galluzzi is interested in several aspects of cell death, stress responses, tumor metabolism, oncogenic signaling pathways and tumor immunology. In 2012, Dr. Galluzzi and collaborators discovered a critical and clinically relevant role for vitamin B6 metabolism in the response of cancer cell to oncogenic and chemotherapeutic stress. Dr. Galluzzi is a founding member of the European Research Institute for Integrated Cellular Pathology
Publications
Manager
LabEx ImmunoOncologie
Université Paris Descartes/Paris V
France
Tel: +33-1-4211-4516
Research Interest
Cell death, autophagy, cancer metabolism, oncogenic signaling pathways, tumor immunology
Susana M. Campos
Susana M. Campos
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
United States
Tel: (617)-632-5269
Biography
Susana Campos, MD received her MD from Georgetown University in 1992, and then completed residency training at Georgetown Medical Center. Between 1995 and 1998, she completed a fellowship in hematology-oncology at Brigham and Women's Hospital, in Boston, and in 2000 received her MPH from Harvard School of Public Health. She serves on committees for the American Society of Clinical Oncology, the Gynecological Oncology Group, and the National Comprehensive Cancer Network. She is board-certified in internal medicine, oncology, and hematology.
Publications
Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
United States
Tel: (617)-632-5269
Research Interest
Gynecologic oncology, Breast oncology
Yaguang Xi
Yaguang Xi
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9857
Biography
Yaguang Xi serves as an Assistant Professor of oncologic sciences at the Mitchell Cancer Institute, University of South Alabama, Mobile, Ala, USA. In 2003, Dr. Xi earned his Ph.D. degree in cancer biology from the Peking University after he accomplished the medical training. His expertise covers molecular biology, cell biology, genomics, genetics, oncology, and bioinformatics. Currently, Dr. Xi focuses on characterizing micro-RNA biomarkers and validating their import function in cancer development, tumor metastasis, chemotherapy, and prevention.
Publications
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9857
Research Interest
Discovery and validation of novel biomarkers associated with tumor progression, metastasis, therapeutic response, and chemoprevention
Identification and characterization of important roles of non-coding RNA (microRNAs) in human cancer
Developing novel normalization methods for microarray analysis
Mitsuhiro Nakamura
Mitsuhiro Nakamura
Assistant professor
Department of Obstetrics and Gynecology
Kanazawa University
Japan
Tel: +81-(0)76-265-2425
Biography
Publications
Assistant professor
Department of Obstetrics and Gynecology
Kanazawa University
Japan
Tel: +81-(0)76-265-2425
Research Interest
Gynecologic oncology, Cancer stem cell, Molecular target therapy
Ajay P. Singh
Ajay P. Singh
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9843
Biography
Publications
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9843
Research Interest
Cancer progression and metastasis; Gene regulation; MicroRNAs in cancer; Mechanisms of therapy-resistance; Molecular diagnosis, prognosis and sub-classification of cancer; Natural products as cancer prevention and therapy agents
Komaraiah Palle
Komaraiah Palle
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9854
Biography
Publications
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9854
Research Interest
Molecular cancer therapeutics, identification of novel drug targets and therapeutics development, DNA damage response and repair pathways, special focus is on Fanconi anemia pathway and homologous recombination, Carcinogenesis and Drug resistance, Cell cycle regulation and DNA replication, DNA topoisomerases and their inhibitors, Posttranslational modifications special focus on ubiquitin ligases and their role in DNA damage response and repair
Peter Eichhorn
Peter Eichhorn
Assistant Professor
Cancer Science Institute of Singapore
Yong Loo Lin School of Medicine
National University of Singapore
Singapore
Biography
Publications
Assistant Professor
Cancer Science Institute of Singapore
Yong Loo Lin School of Medicine
National University of Singapore
Singapore
Research Interest
Peter’s laboratory has a large focus on the application of genome wide shRNA screens to identify novel genes that underlie the sensitivity and resistance to specific targeted therapeutics. I developed expertise in the field of shRNA screens while I was a postdoc in Rene Bernards Laboratory and we studied how the regulation of PP2A phosphatases impact JNK pathway signaling and apoptosis (Eichhorn PJA, PLOS Genetics, 2007). I then continued to explore the use of shRNA screens in a more translational setting when I joined the laboratory of Jose Baselga. Here, I developed a keen interest in understanding how cancers develop resistance to targeted therapies that are currently having an impact in the clinic. Initially, we focused on discovering resistant mechanisms to anti-HER2 inhibitors in HER2 amplified breast cancer (Eichhorn PJA, Cancer Research, 2008; Eichhorn PJA, PNAS, 2011), but have more recently extended to newer targeted therapy paradigms including PI3K and TGFβ inhibitors (Eichhorn PJA, Nature Medicine, 2012; Eichhorn PJA, JCI, in press).
Sudhir Singh
Sudhir Singh
Cancer Immunodiagnostics
Van Andel Research Institute
United States
Tel: (616)-234-5803
Biography
Sudhir Singh received his Ph.D. in Biochemistry and Molecular Biology from the University of Nebraska Medical Center. His PhD work was focused on the relaxin signaling pathway and subsequent activation of peroxisome proliferator-activated receptor gamma. Thereafter, he earned his Postdoctoral Professional Masters in Bioscience Management from the Claremont Colleges Consortium. He haspreviously contributed towards research and business project for Life Technologies. He was involved in conducting technology evaluation of a proprietary assay developed for drug delivery and developing assay requirement for a 3D culture model for ADME to test drug candidates. Currently, he is working with Dr. Brian Haab at Van Andel Research Institute. His current research focuses on the development of glycan based pancreatic cancer biomarkersusing high throughput assays.
Publications
Cancer Immunodiagnostics
Van Andel Research Institute
United States
Tel: (616)-234-5803
Research Interest
Signal transduction, Cancer biology, Cancer Biomarker discovery and development
Rajeev Kumar
Rajeev Kumar
Research Scientist
SentoClone Co Pvt Ltd
China
Biography
Dr Kumar completed his undergraduate and post graduate from Bundelkhand University, India and carried post graduate dissertation at National Institute of Ocenography, India. He then awarded junior and senior research fellowship from Indian Council of Medical Research (ICMR) to pursue PhD at Division of Endocrinology, Central Drug Research Institute (CDRI), which is a premier institute of Council of Scientific and Industrial Research (CSIR) in India. Dr Kumar then joined the University of South Alabama as a postdoctoral fellow in 2011 and his studies investigating role of miRNA in diagnosis of Breast Cancer. Currently, Dr Kumar is working as post doctoral assistant at University of Hull, UK and his research work include investigating prostate cancer stem cell behavior under bone microenvironment, and molecular mechanism involved in primary metastasis.
Publications
Research Scientist
SentoClone Co Pvt Ltd
China
Research Interest
Endocrine Cancer (Prostate and Breast), Phytotherapy, Bone Metastasis, Biomarker and Drug Discovery.
Javier Rodriguez-Ubreva
Javier Rodriguez-Ubreva
Cancer Epigenetics and Biology Programme
Bellvitge Biomedical Research Institute
Spain
Biography
Javier Rodriguez-Ubreva was born in Madrid, Spain, in 1979. He studied Biology at the Alcala University and obtained his PhD in Biomedicine at the same University in 2008 focusing in the role of protein tyrosine phosphatases and kinases in cell cycle and cell migration control in the context of prostate cancer. Then he moved to Bellvitge Biomedical Research Institute in Barcelona for his postdoctoral training in collaboration with Esteban Ballestar in the Epigenetics and Cancer Biology Program. During this period, he focused on the epigenetic regulation at DNA methylation, histone modifications and microRNA level in several cell differentiation models (immune system and myogenesis). Javier Rodriguez-Ubreva has authored several papers including relevant contributions to understanding the function of tyrosine phosphatases and kinases in cancer progression and the epigenetic control in normal and aberrant cell proliferation and differentiation processes.
Publications
Cancer Epigenetics and Biology Programme
Bellvitge Biomedical Research Institute
Spain
Research Interest
Analysis of DNA methylation, histone modifications and microRNAs in cell reprogramming and cell differentiation models
Shanta Raj Bhattarai
Shanta Raj Bhattarai
MD Anderson Cancer Center
The University of Texas
United States
Tel: (713)-745-5230
Biography
Publications
MD Anderson Cancer Center
The University of Texas
United States
Tel: (713)-745-5230
Research Interest
Cancer Nanotechnology, Theranostic Nanoformulation, Targeted Gene/Drug Delivery
Raul Zamora Ros
Raul Zamora Ros
Catalan Institute of Oncology
Bellvitge Biomedical Research Institute
Spain
Tel: (34) 932607401
Biography
Publications
Catalan Institute of Oncology
Bellvitge Biomedical Research Institute
Spain
Tel: (34) 932607401
Research Interest
Polyphenol metabolites as nutritional biomarkers, polyphenols consumption in European population (EPIC study- European Prospective Investigation into Cancer and Nutrition) and their relationships with health, particularly with overall mortality, cancer and CVD.
Erin Eun-Young  Ahn
Erin Eun-Young Ahn
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9805
Biography
Dr. Ahn earned her Ph.D. from the University of Alabama at Birmingham, USA, after completing her undergraduate work in Seoul National University, South Korea. She did her postdoctoral research in Scripps Research Institute and University of California San Diego with special interests in molecular mechanisms of leukemia and roles of RNA splicing. After serving as Assistant Project Scientist at the Moores Cancer Center of the University of California San Diego, Dr. Ahn joined Mitchell Cancer Institute, University of South Alabama as an Assistant Professor in 2012. She heads a lab that is interested in transcriptional control, RNA splicing and non-coding RNA regulation in cancer development and progression, with the goal of identifying novel drug targets for cancer therapy. She is the recipient of numerous professional awards, including international awards for research in leukemia and allied conditions from Lady TATA Memorial Trust.
Publications
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9805
Research Interest
Roles of non-coding RNAs in cancer development and progression, Regulation of transcription and RNA splicing in leukemia and breast cancer, Identification of novel targets for cancer therapy, SON-mediated constitutive/alternative RNA splicing
Seema Singh
Seema Singh
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9844
Biography
Publications
Assistant Professor
Mitchell Cancer Institute
University of South Alabama
United States
Tel: (251)-445-9844
Research Interest
Chemokine signaling in cancer progression, angiogenesis and metastasis,Cancer stem cells
Nuria Mulet-Margalef
Nuria Mulet-Margalef
Institut Català D'oncologia -Idibell
Spain
Biography
Nuria Mulet-Margalef is a doctor specialized in Medical Oncology. She was graduated in 2007 by Universitat Autònoma de Barcelona. During 2008-2012, she performed her specialization in Oncology Department of Hospital Universitari Vall d’Hebron. After this, she joined to the Genitourinary and Sarcomas Group of Vall d’Hebron as clinical investigator. At this moment, she is doing a fellowship in translational investigation in the Sarcoma Research Group of Institut Català d’Oncologia- Idibell. She is interested in the development of new target therapies in soft tissue sarcomas, from preclinical data to clinical trials.
Publications
Institut Català D'oncologia -Idibell
Spain
Research Interest
Sarcomas and Renal Cancer
Alan Prem Kumar
Alan Prem Kumar
Cancer Science Institute of Singapore
Centre for Translational Medicine
National University of Singapore
Singapore
Tel: +65-6516 5456
Biography
Dr. Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Because pyrimidine biosynthesis is an essential step in the progression of secondary Pseudomonas infections, PyrR presents an attractive anti-pseudomonal drug target. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors in the transcriptional regulation of human myeloperoxidase, a leukocyte enzyme implicated as causative agent in atherosclerosis and Alzheimer’s disease. Dr. Kumar relocated back to Singapore to join the Faculty of Medicine, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer biology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is to have a greater understanding of these nuclear receptors – aimed at developing newer selective PPAR gamma modulators, drugs with more potent activity and less toxicity. Towards this end, Dr. Kumar identified a series of 21 structurally new PPAR gamma activators by computer-aided drug design using a combination of ligand-based and structure-based approaches. In collaboration with GenoMed, Inc, USA, he has recently identified a new tyrosine kinase involved in the progression of ovarian, breast, and prostate cancers. Inhibitors were developed against this kinase using computer-aided drug design. In-silico filters were used to eliminate drug compounds with undesirable absorption, distribution, metabolism, excretion and toxicological (ADMET) properties. His goal is to use these drugs to demonstrate its effectiveness in a variety of cancer cell lines, mouse xenograft, with intent to a pilot clinical trial here in Singapore. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.
Publications
Cancer Science Institute of Singapore
Centre for Translational Medicine
National University of Singapore
Singapore
Tel: +65-6516 5456
Research Interest
Alan’s primary research focuses in the areas of signaling by nuclear receptors and oncogenes as well as the development of molecular therapeutics and biomarkers of drug action in human breast cancer. He recently identified a novel oncogene that regulates a key pathway controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. Current research also focuses on developing therapeutic strategies to target this marker with the ultimate aim of conducting translational studies in patients.
Amit A Deorukhkar
Amit A Deorukhkar
MD Anderson Cancer Center
The University of Texas
United States
Tel: (713)-792-0697
Biography
Dr. Deorukhkar completed his undergraduate work (Microbiology) from the University of Mumbai, India. He then completed Ph.D. work at the Bhabha Atomic Research Center, the premier radiobiology research institute in India, for which he received prestigious junior and senior research fellowships from the Department of Atomic Energy, India. Dr. Deorukhkar then joined the University of Texas MD Anderson Cancer Center as a postdoctoral fellow and pursued his studies investigating the role of dietary botanicals in augmenting the effects of cancer radiation therapy and chemotherapy. Dr. Deorukhkar first elucidated a novel mechanism of inducible radioresistance mediated by the NF-B pathway, and then showed that its blockade by plant polyphenol curcumin enhances the efficacy of radiation therapy in colorectal cancer models. Similarly, he showed that the histone deacetylase inhibitor, vorinostat, synergizes with radiation therapy in the treatment of pancreatic cancer. Dr. Deorukhkar is now a research faculty (Instructor) at the Department of Radiation Oncology, MD Anderson Cancer Center and his research interest include investigating the role of dietary phytochemicals and synthetic drugs to augment the effects of radiation therapy and chemotherapy in different cancer types, and to study the detailed molecular mechanisms underlying these effects.
Publications
MD Anderson Cancer Center
The University of Texas
United States
Tel: (713)-792-0697
Research Interest
Radiation Oncology, Molecular Cancer Therapeutics, Molecular Mechanisms of tumor radioresistance, Natural products in Cancer Therapy, Microbiology

top